{
    "clinical_study": {
        "@rank": "25108", 
        "acronym": "CISECON", 
        "arm_group": {
            "arm_group_label": "advagraf", 
            "arm_group_type": "Experimental", 
            "description": "The same capacity advagaf + sirolimus"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the efficacy and safety and Immunosuppressant\n      Therapy Barrier Scale (ITBS) of once daily immunosuppressant maintenance therapy in patients\n      who had kidney transplantations earlier."
        }, 
        "brief_title": "Once-a-day Immunosuppression(CISECON_a_day)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a 6-month, single-arm, multi-center, open-label, continuous cohort study. 160\n      subjects who had kidney transplantations at least 3 months earlier will participate in the\n      study. All enrolled subjects will discontinue the existing Tacrolimus preparations for 6\n      months from enrollment and be converted to Extended Release Tacrolimus at a biologically\n      equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or\n      mycophenolate sodium and be treated with Sirolimus and observed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women at the age of 20 to 65 who had kidney transplantations at least 3 months\n             ago.\n\n          -  Recipients of kidney transplantations from a deceased / cadaveric donor, non-heart\n             beating cadaveric donor / organ donor after cardiac death, or non-blood related or\n             blood related live donor.\n\n          -  Patients being treated with Tacrolimus or Extended Release Tacrolimus as the existing\n             immunosuppressant maintenance therapy.\n\n          -  Able and willing to give informed consent to study participation, having signed the\n             informed consent form according to appropriate procedures, and capable of\n             participating in the study by making visits according to study plans.\n\n        Exclusion Criteria:\n\n          -  HIV, HBsAg, or anti-HCV test positive patients or having received kidney\n             transplantations from an HIV, HBsAg, or anti-HCV test positive donor.\n\n          -  History of severe allergies or hypersensitivities to drugs used in the study or other\n             drugs with a similar chemical structure requiring acute (within the past 4 weeks) or\n             chronic treatment.\n\n          -  Having received other investigational product within 30 days prior to enrollment into\n             this study.\n\n          -  Women of childbearing potential who plan to become pregnant, pregnant and/or\n             lactating women, women who do not intend to use effective contraceptives.\n\n          -  Having uncontrolled diseases or medical conditions requiring continuous treatment.\n\n          -  History of alcohol or drug addiction within the past 3 months or incapable of\n             appropriate communications due to reasons such as mental illness.\n\n          -  Absolute neutrophil count <1,500/mm3 or leukocyte count <2,500/mm3 or platelet count\n             <75,000/mm3 at screening or severe metabolic disorders (including functional\n             disorders).\n\n          -  Having experienced the following condition within the past 1 month:\n\n               -  Serum creatinine > 2.0 mg/dl more than twice.\n\n               -  24 hr urine protein\u2265750 mg/day\n\n               -  Diagnosed with or treated for a rejection reaction or an infection or\n                  hospitalized due to other medical reasons."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964014", 
            "org_study_id": "MED-CT4-11-391"
        }, 
        "intervention": {
            "arm_group_label": "advagraf", 
            "description": "All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.\nadvagrf+sirolimus one time to eat.", 
            "intervention_name": "advagrf", 
            "intervention_type": "Drug", 
            "other_name": "advagrf"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "once", 
        "lastchanged_date": "October 14, 2013", 
        "location": [
            {
                "contact": {
                    "email": "iskwak@pusan.ac.kr", 
                    "last_name": "Ihm Soo Kwak, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Nephrology, Pusan National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ihm Soo Kwak, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dicey97@cha.ac.kr", 
                    "last_name": "Soo Jin Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Gyeonggi-do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Bundang CHA Medical Center,"
                }, 
                "investigator": {
                    "last_name": "Soo Jin Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hansy@paik.ac.kr", 
                    "last_name": "Sang Youb Han, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Gyeonggido", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inje University Ilsan Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Sang Youb Han, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "KHHUH@yuhs.ac", 
                    "last_name": "Ha Huh Kyu, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Kyu Ha Huh, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "yjkwon@korea.ac.kr", 
                    "last_name": "Young Joo Kwon, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Young Joo Kwon, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kmhyj.kim@samsung.com", 
                    "last_name": "Sung Joo Kim, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Soonchunhyang University Hosptial"
                }, 
                "investigator": {
                    "last_name": "Sung Joo Kim, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jeonjs@schmc.ac.kr", 
                    "last_name": "Jin Seok Jeon, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Soonchunhyang University Hosptial"
                }, 
                "investigator": {
                    "last_name": "Jin Seok Jeon, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hrcho@uuh.ulsan.kr", 
                    "last_name": "Hong Rae Cho, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Ulsan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Dept. of Surgery, Ulsan University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hong Rae Cho, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Investigation for Safety and Efficacy, Patient Reported Outcomes of the Conversion to ONce-a-day Immunosuppression After Kidney Transplantation", 
        "overall_contact": {
            "email": "FORSAKE326@ajou.ac.kr", 
            "last_name": "yun-kyoung kim, CRA", 
            "phone": "+82-31-219-4467"
        }, 
        "overall_official": {
            "affiliation": "Ajou University School of Medicine", 
            "last_name": "chang-kwon oh, M.D.,Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to investigate the efficacy of Advagraf \u00ae (Extended Release Tacrolimus) at 6 months after immunosuppressant conversion to the once daily therapy. The efficacy is defined as the incidence rate of composite endpoints of efficacy failure (acute rejection reaction treated or confirmed by biopsy, loss of graft, death, or lost to follow-up).", 
            "measure": "acute rejection reaction treated or confirmed by biopsy, loss of graft, death, or lost to follow-up", 
            "safety_issue": "No", 
            "time_frame": "6months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964014"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ajou University School of Medicine", 
            "investigator_full_name": "Chang kwon oh", 
            "investigator_title": "Professor,Department of surgery, Ajou University School of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference in renal functions (eGFR by MDRD method), urine protein excretion and P/C ratio (A/C ratio), transplant kidney biopsy histology (if biopsy is performed).", 
                "measure": "renal functions", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "Frequency and severity of adverse events and serious adverse events", 
                "measure": "serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "Treatment impact on cardiovascular health: blood pressure and cardiovascular events (acute myocardial infarction, unstable angina pectoris, heart failure, stroke).", 
                "measure": "cardiovascular health", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "Incidence rate of new onset diabetes after transplantation (NODAT) requiring treatment.", 
                "measure": "NODAT", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "Frequency of anemia, leucopenia, and thrombocytopenia.", 
                "measure": "hematology issue", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }
        ], 
        "source": "Ajou University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ajou University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}